Chandra Vargeese has sold WVE and made no open-market buys since Nov 2017

Dr. Chandra Vargeese is a corporate insider and Chief Technology Officer at Wave Life Sciences Ltd. (WVE), where she also serves as Head of Platform Discovery Sciences and sits on the company’s executive leadership team.( She joined Wave in 2014 as Senior Vice President and Head of Research and was appointed Chief Technology Officer in 2020, with responsibility for advancing the company’s PRISM™ platform, which integrates oligonucleotide chemistry, multiple RNA-targeting modalities, and human genetics to drive Wave’s drug discovery and development efforts.( As a senior executive, she has been reported in public filings as a trading insider of Wave Life Sciences Ltd.(

Vargeese is widely recognized as one of the industry’s leading oligonucleotide chemists, with roughly three decades of experience in nucleic acid and RNA therapeutics research and development.( Before Wave, she held senior R&D roles at major pharmaceutical and biotech companies, including Executive Director of Chemistry and Delivery in the RNA Therapeutics Division at Novartis, leadership of siRNA delivery within the RNA Therapeutics division at Merck & Co., and Vice President of Chemistry at Sirna Therapeutics, which Merck acquired for $1.1 billion.( Earlier in her career, she served as Associate Director of Chemistry at NeXstar Pharmaceuticals and is co‑inventor of Macugen® (pegaptanib), an FDA‑approved aptamer therapy for wet age‑related macular degeneration.( Vargeese earned her PhD in organic chemistry from the Indian Institute of Science, Bangalore, and completed post‑doctoral research at the University of Rhode Island, underpinning her long-standing leadership in nucleic acid therapeutics and stereopure oligonucleotide technologies.(

Written by Perplexity from public sources.